RxDoctor Payments Data

Jose Vera

Psychiatric/Mental Health · Sanford, FLNPI 1669702270

Payments from drug & device makers

$4,656in general payments, 2019–2025

Across 197 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$982
  • AbbVie$759
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$646
  • Otsuka America Pharmaceutical, Inc.$538
  • E.r. Squibb & Sons, L.L.C.$350
  • Alkermes, Inc.$299
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,656100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,656 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$63,933
Medicare patients
348
Services billed
544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine41$238,656
RexultiBrexpiprazole67$131,614
IngrezzaValbenazine Tosylate16$129,320
Abilify MaintenaAripiprazole28$84,852
VraylarCariprazine Hcl47$66,398
Invega SustennaPaliperidone Palmitate25$58,554
CaplytaLumateperone Tosylate30$46,342
Aripiprazole163$18,137
Lurasidone Hcl64$17,228
Duloxetine Hcl309$10,067
BelsomraSuvorexant15$6,565
Quetiapine Fumarate298$6,170
Buspirone Hcl334$5,900
Ziprasidone Hcl59$4,765
Chlorpromazine Hcl20$3,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$982$238,65641 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$538$216,46695 claims
Neurocrine Biosciences, Inc.Ingrezza$187$129,32016 claims
AbbVieVraylar$759$66,39847 claims
Johnson & JohnsonInvega Sustenna$205$58,55425 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$646$46,34230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Sanford

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →